COPENHAGEN (Reuters) - Danish biotech company Genmab on Wednesday announced an expansion of its Duobody antibody technology collaboration with Janssen Biotech, a part of Johnson & Johnson. Genmab said it will receive an initial payment of $2 million and potentially will be entitled to milestone and license payments of as much as $174 million to $219 million for each of ten additional programmes. (Reporting by Teis Jensen; Editing by David Goodman) via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment